We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Test That Accurately Measures DNA Damage in Sperm Could Improve Male Infertility Diagnosis

By LabMedica International staff writers
Posted on 25 Jan 2022
Print article
Illustration
Illustration

A new test that can measure the amount of DNA damage in sperm with greater accuracy than current tests could significantly improve diagnosis of male infertility, which is more important than ever now that infertility rates are mounting.

A team of researchers at Tongji Medical College (Wuhan, China) developed a method that detects the number of DNA breaks in sperm, which in turn enables the calculation of the mean number of DNA breaks (MDB) per sperm in a sample. Current tests only show whether or not sperm have DNA damage and do not measure the amount of damage, even though the latter is essential for a complete evaluation of sperm health. However, this information plays a crucial role in guiding fertility treatments and in selecting high-quality sperm for sperm banks.

The researchers first evaluated their new method using sperm samples from 80 patients, 34 of whom had athenospermia (low sperm motility) and 46 of whom had normal semen. The team compared the ability of MDB to differentiate between athenospermia and normal samples with that of a conventional sperm DNA test that assesses the sperm DNA fragmentation index (DFI). From this, the researchers found that the area under the curve of MDB (0.7932) was higher than that of DFI (0.7631), meaning that MDB did a better job of telling the two sample types apart.

To further evaluate MDB’s clinical utility, the team then used it and DFI to assess 49 semen samples, 22 of which were associated with pregnancy and 27 of which were linked to an inability to get pregnant. The researchers found that the difference in MDB between the pregnant and non-pregnant groups was statistically significant (P=0.0106), while the difference in DFI between the two groups was not significant (P=0.0548). Furthermore, the area under the curve of MDB in this case (0.7576) was once again higher than the area under the curve of DFI (0.6616). Taken altogether, this means that MDB identifies viable sperm that lead to pregnancy with greater accuracy than conventional sperm DNA tests.

“These data indicated that the MDB parameter had stronger clinical relevance with the pregnancy outcomes and our established method could provide a better tool to evaluate sperm quality and male fertility,” said Xianjin Xiao, PhD, of Tongji Medical College, who led the team. “Our method involves direct detection of actual DNA fragmentation, which can measure the specific degree of sperm DNA fragmentation. The method has the advantages of short time-consumption, simple operation, high analytical sensitivity, and low requirement for instruments, which are conducive to the popularization of clinical application.”

Related Links:
Tongji Medical College 

Gold Supplier
COVID-19 Immune Response Test
Quan-T-Cell
New
Automatic Hematology Analyzer
BF-7200Plus
New
Automatic Immunoassay Analyzer
PATHFAST
New
Homogenizer
DP0150 Pulse 150

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.